STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

  1. Home
  2. Sec-filings
  3. APVO
  4. [EFFECT] Aptevo Therapeutics Inc. SEC Filing

[EFFECT] Aptevo Therapeutics Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
EFFECT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: November 25, 2025 4:00 P.M.
Form: S-1
CIK: 0001671584
Company Name: Aptevo Therapeutics Inc.
File Number: 333-290663

Source: View Original Filing on SEC EDGAR

Stock APVO logo
Aptevo Therapeutics Inc

NASDAQ:APVO

APVO Rankings

#5948 Ranked by Market Cap
N/A Ranked by Dividends

APVO Latest News

Nov 10, 2025
Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors
Nov 6, 2025
Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update
Oct 8, 2025
Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter
Sep 16, 2025
Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML
Sep 4, 2025
Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules

APVO Latest SEC Filings

Nov 25, 2025
[424B4] Aptevo Therapeutics Inc. Prospectus Filed Pursuant to Rule 424(b)(4)
Nov 12, 2025
[Form 4] Aptevo Therapeutics Inc. Insider Trading Activity
Nov 6, 2025
[10-Q] Aptevo Therapeutics Inc. Quarterly Earnings Report
Nov 6, 2025
[8-K] Aptevo Therapeutics Inc. Reports Material Event
Oct 30, 2025
[8-K] Aptevo Therapeutics Inc. Reports Material Event

APVO Stock Data

23.42M
16.84M
0%
0.48%
3.11%
Biotechnology
Pharmaceutical Preparations
Link
United States
SEATTLE